Drug Interaction Between Atomoxetine (Strattera) and Lorazepam (Ativan)
There is no clinically significant pharmacokinetic or pharmacodynamic interaction between atomoxetine and lorazepam, and they can be safely co-administered with standard monitoring.
Pharmacological Basis for Safety
Distinct Metabolic Pathways
- Atomoxetine is primarily metabolized via CYP2D6, with no involvement of glucuronide conjugation pathways 1, 2
- Lorazepam is metabolized exclusively through glucuronide conjugation in the liver, with no CYP450 involvement 3
- These completely separate metabolic pathways eliminate the risk of pharmacokinetic drug-drug interactions
No Evidence of CYP450-Mediated Interactions
- Atomoxetine does not inhibit or induce CYP enzymes that would affect other medications 2, 4
- In vitro studies demonstrated atomoxetine causes minimal inhibition of CYP1A2, CYP2C9, CYP2D6, and CYP3A at therapeutic concentrations 4
- Clinical studies with probe substrates (desipramine for CYP2D6, midazolam for CYP3A) showed no clinically significant alterations in pharmacokinetics when co-administered with atomoxetine 4
Mechanism of Action Considerations
Complementary Rather Than Conflicting Effects
- Atomoxetine selectively inhibits norepinephrine reuptake, increasing noradrenaline and dopamine in the prefrontal cortex 1, 5
- Lorazepam activates GABA-A receptors, providing anxiolytic and sedative effects through a completely different neurotransmitter system 3
- There is no pharmacodynamic overlap that would create additive toxicity or serotonin syndrome risk
Clinical Monitoring Recommendations
Standard Safety Monitoring
- Monitor cardiovascular parameters (heart rate and blood pressure) as atomoxetine causes mild increases (1-2 bpm heart rate, 1-4 mmHg blood pressure) 1
- Assess for excessive sedation from lorazepam, particularly in elderly patients who are more sensitive to benzodiazepine effects 3
- Watch for respiratory depression with lorazepam, especially if other CNS depressants (particularly opioids) are also prescribed 3
Atomoxetine-Specific Precautions
- Monitor for suicidal ideation, particularly in children and adolescents during the first few months of treatment or after dose changes 1
- Assess liver function if jaundice or signs of hepatic dysfunction develop 1
- Consider CYP2D6 metabolizer status if adverse effects are prominent, as poor metabolizers have 10-fold higher plasma concentrations 2
Lorazepam-Specific Precautions
- Avoid prolonged high-dose lorazepam (>1 mg/kg/day total daily dose) due to risk of propylene glycol toxicity manifesting as metabolic acidosis and acute kidney injury 3
- Monitor serum osmol gap if using lorazepam continuously; values >10-12 mOsm/L suggest propylene glycol accumulation 3
Important Contraindications to Remember
Atomoxetine Contraindications
- Concomitant use with MAOIs is absolutely contraindicated due to serotonin syndrome risk 1
- Caution with other serotonergic agents (SSRIs, SNRIs, tramadol, dextromethorphan) though lorazepam is not serotonergic 6
No Interaction with Benzodiazepines
- Benzodiazepines like lorazepam are not listed among medications that interact with atomoxetine in comprehensive drug interaction studies 4
- The combination does not create the cardiopulmonary instability risk seen when benzodiazepines are combined with opioids 3
Clinical Context
This combination may actually be therapeutically beneficial in patients with ADHD and comorbid anxiety disorders, as atomoxetine may be particularly useful for patients with comorbid anxiety 1, 5. The medications address different symptom domains without interfering with each other's metabolism or mechanism of action.